Pre-implantation genetic aneuploidy screening (PGAS)

Pre-Implantation Genetic Aneuploidy Screening aims to improve the chance of having a healthy live birth in the following patient groups:

• Women aged 40 and above

• Couples who have undergone at least three fresh IVF cycles without success

• Women who suffer from recurrent miscarriages.

It is known that chromosomally abnormal (aneuploid) embryos contribute to poor IVF outcome. PGAS allows the analysis of specific chromosomes to be performed on a single cell removed from an embryo of 5 cells or more. Following chromosomal analysis only the embryos that test normal for the chromosomes analysed are selected for transfer to the uterus. By not transferring chromosomally abnormal embryos, PGAS can increase the chances of a successful outcome.